Aerosol carbenicillin and gentamicin treatment of Pseudomonas aeruginosa infection in patients with cystic fibrosis.
about
Inhaled therapy in cystic fibrosis: agents, devices and regimensClinical applications of pulmonary delivery of antibioticsDistribution and function of the peptide transporter PEPT2 in normal and cystic fibrosis human lung.Molecular mechanisms of pulmonary peptidomimetic drug and peptide transport.Nebulised antipseudomonal antibiotic therapy in cystic fibrosis: a meta-analysis of benefits and risks.Pseudomonas aeruginosa infection in patients with cystic fibrosis: scientific evidence regarding clinical impact, diagnosis, and treatmentFrequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection.The role of nebulized antibiotics in treating serious respiratory infections.Clinical significance of microbial infection and adaptation in cystic fibrosis.Iseganan HCl: a novel antimicrobial agent.New drugs in respiratory disorders: II.Influence of pulmonary surfactant on in vitro bactericidal activities of amoxicillin, ceftazidime, and tobramycinAerosol delivery of liposome-encapsulated ciprofloxacin: aerosol characterization and efficacy against Francisella tularensis infection in mice.Urinary N-acetyl-beta-D-glucosaminidase activity in patients with cystic fibrosis on long-term gentamicin inhalation.Improvement of nebulised antibiotic delivery in cystic fibrosis.Lung infections. 3. Pseudomonas aeruginosa and other related species.Long-term follow up of changes in FEV1 and treatment intensity during Pseudomonas aeruginosa colonisation in patients with cystic fibrosis.Effect of tonicity of nebulised colistin on chest tightness and pulmonary function in adults with cystic fibrosis.Pseudomonas cepacia: a new pathogen in patients with cystic fibrosis referred to a large centre in the United KingdomManaging adults with cystic fibrosis.Nebulized antibiotic therapy: the evidence.Factors influencing the size distribution of aerosols from jet nebulisers.Recent advances in respiratory medicine.Respiratory and allergic disease. II. Chronic obstructive airways disease and respiratory infectionsDelivery of antibiotics to the respiratory tract: an update.Tobramycin administered by the TOBI(®) Podhaler(®) for persons with cystic fibrosis: a review.Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health.Mechanisms of absorption and elimination of drugs administered by inhalation.In vitro assessment of combined antibiotic and mucolytic treatment for Pseudomonas aeruginosa infection in cystic fibrosis.Antibacterial and anti-inflammatory activity of a temporin B peptide analogue on an in vitro model of cystic fibrosis.Therapeutic aerosols 2--Drugs available by the inhaled route.Protection by antibiotics against myeloperoxidase-dependent cytotoxicity to lung epithelial cells in vitro.The effect of alginate lyase on the gentamicin resistance of Pseudomonas aeruginosa in mucoid biofilms.Pseudomonas aeruginosa bronchopulmonary infection in late human immunodeficiency virus disease.Aerosol antibiotic treatment in cystic fibrosis.Evaluation of jet nebulisers for use with gentamicin solutionInhaled antibiotics in cystic fibrosis: a review.Nebulised antibiotics for adults with cystic fibrosis.Pseudomonas infections in cystic fibrosis.Comparison of lung deposition of colomycin using the HaloLite and the Pari LC Plus nebulisers in patients with cystic fibrosis.
P2860
Q26797450-7A21015D-1862-4A3E-AA25-036BFA7C97BBQ26996053-DE24E70F-37B9-4820-8DC4-CB45DA61A2D8Q33183310-2E75C5D6-FDB1-4985-9041-A193DA80FB18Q33198362-35A4AC92-B5F7-491F-8EFD-B8AE75E25649Q33775986-93F2B747-43E3-4415-B91B-9C511849CB22Q33824149-216B2BB7-59D9-4592-8F79-687E4FA0A301Q34056063-CE40CFAA-2714-4E2C-B123-856BAA954FEEQ34393840-924B449A-0A39-456D-9BC7-C07AF423F4E7Q34491552-2A69CA9F-6E06-483C-A453-08F06E1B4F4BQ34768583-808ADC2F-C617-4856-B4A6-7D124072485FQ34991833-AA7E2638-9D83-43D8-9D8F-AFB053719986Q35111428-16C4D84A-6912-41E5-83A9-FFD8BF7FDD7AQ35136593-A9737F92-2B5F-406D-9E17-B7EF61273734Q35259843-1A5ECCA6-25AB-43F5-9583-0D3233037F3EQ35262999-29274CA5-F51B-4237-9406-D24BD28767CEQ35532283-D3F0B6F2-A661-41D0-A1A3-5BB2C9D8CD7CQ35532709-C58FBEB1-D57F-4D1C-9D8C-18116CDB0BB5Q35563665-BE9F73DC-9FC1-4431-8225-FFC0B18C61CBQ35625399-D6C07EA4-1E0C-4E7B-9500-895E08E5472AQ35708784-10A90234-AA4F-477C-BCE5-F3E9EF72603DQ36310044-8C02E09E-B7F8-4142-B8B1-480843BCB632Q36619612-6EFC88E4-8F68-4A5D-B84A-C40C045C61F4Q36704303-DAEEE19C-9BA3-4F5F-87C4-3247CB83E61AQ36894089-CDE00434-CA13-4FC2-8304-A5F263F13353Q37564542-96D646DB-9FE3-4F75-AA15-957CDDF372F6Q38037076-56F6EE36-6865-4CCC-A739-1B3CDFEA3404Q38094297-0B055392-908B-4107-BB63-64F1C96B7767Q38126941-68C1B0D7-60BE-4D01-89CF-B2F36972F29CQ38942310-460C6A7A-9DE7-47D2-8C83-072E6A6BA28FQ38958442-C2D73FAF-C777-4E9D-884C-E49343CFFBD3Q40093004-B2A0962E-F814-4C18-BCDC-1A3EB4243BC5Q40512604-CFCA9199-1298-4057-BCD4-E63A66CD6A86Q40721650-D79D4401-E2F2-4B4F-8225-1F38E9FEE911Q40768826-D765DA1F-8183-49E0-B0D2-F320A62623D3Q40826267-0888BFD5-2A21-4143-8CE4-90AE5E778851Q41123563-5B5DB8C0-9810-4FD9-B527-122673C9959DQ41127253-DA640410-004E-465C-BA71-1055E1869870Q41810487-AFD1BFA6-6E74-4B14-A804-89367A608092Q41819894-B24AFCA3-8CBA-4F10-90B4-F2A86CC718D0Q41847225-6B184529-958A-4B80-9399-0CBA63D9FB32
P2860
Aerosol carbenicillin and gentamicin treatment of Pseudomonas aeruginosa infection in patients with cystic fibrosis.
description
1981 nî lūn-bûn
@nan
1981 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1981 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1981年の論文
@ja
1981年論文
@yue
1981年論文
@zh-hant
1981年論文
@zh-hk
1981年論文
@zh-mo
1981年論文
@zh-tw
1981年论文
@wuu
name
Aerosol carbenicillin and gent ...... patients with cystic fibrosis.
@ast
Aerosol carbenicillin and gent ...... patients with cystic fibrosis.
@en
Aerosol carbenicillin and gent ...... patients with cystic fibrosis.
@nl
type
label
Aerosol carbenicillin and gent ...... patients with cystic fibrosis.
@ast
Aerosol carbenicillin and gent ...... patients with cystic fibrosis.
@en
Aerosol carbenicillin and gent ...... patients with cystic fibrosis.
@nl
prefLabel
Aerosol carbenicillin and gent ...... patients with cystic fibrosis.
@ast
Aerosol carbenicillin and gent ...... patients with cystic fibrosis.
@en
Aerosol carbenicillin and gent ...... patients with cystic fibrosis.
@nl
P2093
P921
P1433
P1476
Aerosol carbenicillin and gent ...... patients with cystic fibrosis.
@en
P2093
A R Penketh
J C Batten
M E Hodson
P304
P356
10.1016/S0140-6736(81)90588-2
P407
P577
1981-11-01T00:00:00Z